← Leaderboards
Herman O Sintim
Univ Of Maryland, College Park
$5,929,990
Attributed
$13,013,005
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,013,005 · 7
By mechanism
R01$10,613,074 · 5
R44$1,999,998 · 1
R41$399,933 · 1
Top collaborators
- Xiaofeng Frank Yang6 shared
- Danzhou Yang5 shared
- Reuben Kapur4 shared
- Sergei I Sukharev4 shared
- Jie Wu4 shared
- Andriy Anishkin3 shared
- Frederick Wayne Holtsberg3 shared
- Funda Meric-Bernstam3 shared
Most similar at Univ Of Maryland, College Park
Same institution · by research overlap
- Andriy Anishkin$272,628
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsIn VivoDrug TargetingInhibitorPropertyLeadIn VitroMalignant NeoplasmsPathway InteractionsDesignScaffoldResistanceMutationChemistryScreeningAffinityAntineoplastic AgentsToxic EffectMutantKinase InhibitorOralPhosphotransferasesResponseCancer Cell
Grant awards (26)
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$580,663
R01 · FY2025 · CA
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors$461,983
R01 · FY2025 · CA · contact PI
Targeting MYC promoter G-quadruplex for MYC inhibition by Indenoisoquinolines$387,242
R01 · FY2025 · CA
Targeting Cyclic Dinucleotide Signaling Pathways to Interrupt the Nature Cycle of Borrelia burgdorferi$560,225
R01 · FY2024 · AI
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$551,629
R01 · FY2024 · CA
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors$434,910
R01 · FY2024 · CA · contact PI
Targeting MYC promoter G-quadruplex for MYC inhibition by Indenoisoquinolines$367,880
R01 · FY2024 · CA
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$567,912
R01 · FY2023 · CA
Targeting Cyclic Dinucleotide Signaling Pathways to Interrupt the Nature Cycle of Borrelia burgdorferi$560,225
R01 · FY2023 · AI
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors$452,225
R01 · FY2023 · CA · contact PI
Targeting MYC promoter G-quadruplex for MYC inhibition by Indenoisoquinolines$381,381
R01 · FY2023 · CA
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$612,099
R01 · FY2022 · CA
Targeting Cyclic Dinucleotide Signaling Pathways to Interrupt the Nature Cycle of Borrelia burgdorferi$591,225
R01 · FY2022 · AI
3H-pyrazolo[4,3-f]quinoline-containing compounds as selective and tunable protein kinase inhibitors$495,845
R01 · FY2022 · CA · contact PI
Pathogenesis of Alzheimer's Disease upon Borrelia burgdorferi infection in a mouse model system$396,250
R01 · FY2022 · AI
Targeting MYC promoter G-quadruplex for MYC inhibition by Indenoisoquinolines$385,297
R01 · FY2022 · CA
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor$999,998
R44 · FY2021 · CA
Targeting Cyclic Dinucleotide Signaling Pathways to Interrupt the Nature Cycle of Borrelia burgdorferi$626,225
R01 · FY2021 · AI
Targeting MYC promoter G-quadruplex for MYC inhibition by Indenoisoquinolines$393,161
R01 · FY2021 · CA
Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor$1,000,000
R44 · FY2020 · CA
Targeting Cyclic Dinucleotide Signaling Pathways to Interrupt the Nature Cycle of Borrelia burgdorferi$659,925
R01 · FY2020 · AI
Aminonaphthyridine compounds as potential therapeutics for lung and thyroid cancers$399,933
R41 · FY2020 · CA
The bacterial mechanosentitive channel as a multimodal sensor device$272,628
R01 · FY2016 · GM
The bacterial mechanosentitive channel as a multimodal sensor device$272,628
R01 · FY2015 · GM
The bacterial mechanosentitive channel as a multimodal sensor device$272,628
R01 · FY2014 · GM
The bacterial mechanosentitive channel as a multimodal sensor device$328,888
R01 · FY2013 · GM